Anaveon presents new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Basel, Novmeber 9, 2024 – Anaveon, a clinical stage, immuno-oncology company, presents posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas. Abstracts will be available online (Journal for ImmunoTherapy of Cancer (JITC)) from 8 a.m. CST on November 5, 2024.

Details of the poster presentations are:

Saturday, Nov. 9, 2024, 12:15 – 1:45 pm CST

Poster #960 (download poster #960 here)
Title: ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells
Authors: A. Rau, N. Egli, P. Murer, L. Petersen, C. Stocker, K. Richter, C. Huber

Poster #954 (download poster #954 here)
Title: ANV600, a cis-signaling αPD-1/IL-2Rβ/γ agonist, expands both CD4+ and CD8+ tumor-specific T cells by acting in the tumor microenvironment and draining lymph nodes
Authors: P. Murer, A. Zurbach, L. Petersen, N. Egli, A. Katopodis, C. Huber

Latest News

10.12.2025

Anaveon announces poster presentation at the 2025 European Society for Medical Oncology – Immuno-Oncology (ESMO-IO) Congress

— Anaveon will present further progress in EXPAND-1, a Phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors — Basel, December 10, 2025 – Anaveon, a global clinical stage, immuno-oncology company, will present a…
Read more

27.10.2025

Anaveon announces poster presentation at the 2025 American College of Rheumatology Convergence

— Anaveon will present ANV200, a novel, highly potent Fc-engineered anti-PD-1 agonistic antibody designed to deplete pathogenic T cells expressing high to low levels of PD-1 — Basel, October 27, 2025 – Anaveon, a global clinical stage, immunology company, will present a poster on ANV200 at…
Read more

19.10.2025

Anaveon announces poster presentation at the 2025 European Society for Medical Oncology Annual Meeting

— Anaveon will present progress in EXPAND-1, a Phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors — Basel, October 19, 2025 – Anaveon, a global clinical stage, immuno-oncology company, will present a…
Read more

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com